Objective : To investigate the method and evaluation of using different doses of vancomycin(VCM) to construct an acute kidney injury(AKI) model in SD rats. Methods : The 6-week-old male SD rats were randomly divided into 4 groups: normal control(NC) group, VCM(200, 400, 600) mg/kg group. The drug was given by intraperitoneal injection once a day for 7 days. The levels of blood urea nitrogen(BUN) and creatinine(Cre) were detected. The kidney was weighed and the kidney body ratio was calculated. Renal tissue was stained with HE and PAS, and the pathological injury of kidney was observed under light microscope. Results : With the increase of VCM dose, serum BUN and Cre levels in each dose group showed an upward trend(F=3.85,P<0.05;F=9.02,P<0.01). Compared with the VCM(200, 400) mg/kg groups, the Cre level in the VCM 600 mg/kg group was the highest, with statistically significant differences(P<0.01,P<0.05). As the VCM dose increased, body weight of rats in each dose group decreased(F=54.81,P<0.01), while total kidney weight and kidney body ratio increased(F=11.13,F=14.43, bothP<0.01). Significant statistically differences(P<0.01,P<0.05)were observed in body weight, total kidney weight and kidney body ratio between the VCM 600 mg/kg group and the VCM(200, 400) mg/kg groups. HE staining and PAS staining showed that renal tubules in each dose group were damaged to varying degrees. With the increase of VCM dose, the pathological score of kidney injury increased(F=105.80,F=28.89, bothP<0.01), and the pathological damage of renal tubular epithelial cells such as shedding, swelling and cast formation was the most serious in VCM 600 mg/kg group. Conclusion The AKI model in rats can be stably established by intraperitoneal injection of VCM at 600 mg/kg once a day for 7 days.

Objective To explore the predictive value of artificial intelligence(AI)quantitative model for pathological subtypes of stage Ⅰ invasive lung adenocarcinoma with ground glass nodule(GGN).Methods A total of 118 cases(124 lesions)of GGN patients with stage Ⅰ invasive lung adenocarcinoma confirmed by surgery and pathology were analyzed retrospectively,and they were divided into lepidic predominant adenocarcinoma(LPA)group(46 lesions)and non-lepidic predominant adenocarcinoma(n-LPA)group(78 lesions)according to the pathological subtype results.Some relevant AI quantitative parameters were recorded,including the longest diameter,total volume,the percentage of solid volume,total mass,the percentage of solid mass,maximum CT value,minimum CT value,and average CT value.The independent predictors of n-LPA were screened by univariate and multivariate logistic regression analysis,the independent risk factors were quantified by Nomogram,and the diagnostic efficiency of the model was evaluated by using receiver operating characteristic(ROC)curve.Results Binomial logistic regression analysis showed that the percentage of solid mass[odds ratio(OR)=1.965,95％confidence interval(CI)1.515-2.549]and average CT value(OR=1.020,95％CI 1.004-1.036)were independent predictors of n-LPA(P＜0.05).The Nomogram to quantify the independent risk factors showed that the above prediction model was in good agreement with the actual results,and the C-index value was 0.872(95％CI 0.791-0.953).ROC curve analysis showed that the diagnostic performance of the combination of the above two indexes[area under the curve(AUC)=0.829]was better than that of the solid mass percentage(AUC=0.788)and the average CT value(AUC=0.765)of the single indexes,and the corresponding sensitivity and specificity were 87.2％and 84.8％,respectively,which were consistent with the pathological results(Kappa=0.667).Conclusion The percentage of solid mass and the average CT value in the AI quantitative model can effectively help predict the pathological subtypes of GGN stage Ⅰ invasive lung adenocarcinoma,and the combination of the above two indicators can improve the differential diagnosis efficiency of CT between LPA and n-LPA.

Objective To evaluate the efficacy of 0.3％ sodium hyaluronate ophthalmic solution in mild-to-moderate dry eye patients.Metbods A prospective,multicenter,and self-controlled clinical trial was performed on 200 patients who were diagnosed as mild-to-moderate dry eye from January 2015 to June 2017 in Eye Institute of Xiamen University,Eye & ENT Hospital of Fudan University,Zhongshan Ophthalmic Center,Xiangya Hospital Central South University,Eye Hospital of Wenzhou Medical University,and Beijing Tongren Hospital,Capital Medical University.The study protocol was approved by the Ethics Committees of Eye Institute of Xiamen University,written informed consent was obtained from each patient prior to any medical examination.All patients were treated with 0.3％ sodium hyaluronate ophthalmic solution 6 times per day (one drop each time) for 28 days.Corneal fluorescein sodium staining,tear film break-up time (BUT),Schirmer Ⅰ test (S Ⅰ t),degree of conjunctival hyperemia,eyelid margin,meibomian gland secretion,secretory capacity of meibomian gland and subjective symptoms were assessed at baseline,on the 14th day and 28th day after treatment.Bulbar impression cytology was evaluated at baseline and on the 28th day after treatment.Irritation of 0.3％ sodium hyaluronate ophthalmic solution was estimated on the 14th day and 28th day after treatment.Results The total score of subjective symptoms,BUT,S Ⅰ t,degree of conjunctival hyperemia were significantly different among different treatment time points (F =108.969,27.598,16.838,36.750;all at P＜0.01).Compared with before treatment,the total score of subjective symptoms was significantly decreased,the degree of conjunctival hyperemia and the total corneal fluorescein sodium staining point number were significant decreased on the 14th day and 28th day after treatment.The total score of subjective symptoms,degree of conjunctival hyperemia and total corneal fluorescein sodium staining point number on the 28th day after treatment were significant lower than those on the 14th day after treatment.Compared with before treatment,the BUT was significantly longer and the S Ⅰ t scores were significantly increased on the 14th day and 28th day after treatment.The BUT on the 28th day after treatment was significantly longer than that on the 14th day after treatment;no significant difference in S Ⅰ t was observed between the 28th day and the 14th day after treatment.The scores of palpebral margin change,meibomian gland secretory ability and secretion characteristics were not significantly different among different treatment time points(H=0.255,2.356,0.294;all at P＞0.05).The impression cytology grade on the 28th day after treatment was 1.08±0.74,which was significantly lower than 1.53±0.76 before treatment (t =5.979,P＜0.01).The number of goblet cells on the 28th day after treatment was significantly higher than that before treatment (U =1 806.500,P＜ 0.01).On the 14th day after treatment,70％ of the patients indicated that the drug was non-irritating,and no patient had intolerable irritation affecting daily lives.All patients had good tolerance to this drug.Conclusions The use of 0.3％ sodium hyaluronate eye drops can improve the symptoms and signs of mild to moderate dry eye,which can be widely used for mild-to-moderate dry eye patients in clinic.

Objective To evaluate the efficacy of 0. 3％ sodium hyaluronate ophthalmic solution in mild.to. moderate dry eye patients. Methods A prospective,multicenter,and self.controlled clinical trial was performed on 200 patients who were diagnosed as mild.to.moderate dry eye from January 2015 to June 2017 in Eye Institute of Xiamen University,Eye &ENT Hospital of Fudan University,Zhongshan Ophthalmic Center,Xiangya Hospital Central South University, Eye Hospital of Wenzhou Medical University, and Beijing Tongren Hospital, Capital Medical University. The study protocol was approved by the Ethics Committees of Eye Institute of Xiamen University,written informed consent was obtained from each patient prior to any medical examination. All patients were treated with 0. 3％ sodium hyaluronate ophthalmic solution 6 times per day ( one drop each time) for 28 days. Corneal fluorescein sodium staining,tear film break.up time (BUT),SchirmerⅠtest (SⅠt),degree of conjunctival hyperemia,eyelid margin,meibomian gland secretion,secretory capacity of meibomian gland and subjective symptoms were assessed at baseline,on the 14th day and 28th day after treatment. Bulbar impression cytology was evaluated at baseline and on the 28th day after treatment. Irritation of 0. 3％ sodium hyaluronate ophthalmic solution was estimated on the 14th day and 28th day after treatment. Results The total score of subjective symptoms,BUT,SⅠt,degree of conjunctival hyperemia were significantly different among different treatment time points( F=108. 969,27. 598,16. 838,36. 750;all at P<0. 01). Compared with before treatment,the total score of subjective symptoms was significantly decreased, the degree of conjunctival hyperemia and the total corneal fluorescein sodium staining point number were significant decreased on the 14th day and 28th day after treatment. The total score of subjective symptoms,degree of conjunctival hyperemia and total corneal fluorescein sodium staining point number on the 28th day after treatment were significant lower than those on the 14th day after treatment. Compared with before treatment,the BUT was significantly longer and the SⅠt scores were significantly increased on the 14th day and 28th day after treatment. The BUT on the 28th day after treatment was significantly longer than that on the 14th day after treatment;no significant difference in SⅠt was observed between the 28th day and the 14th day after treatment. The scores of palpebral margin change,meibomian gland secretory ability and secretion characteristics were not significantly different among different treatment time points(H=0. 255,2. 356,0. 294;all at P>0. 05). The impression cytology grade on the 28th day after treatment was 1. 08±0. 74,which was significantly lower than 1. 53±0. 76 before treatment (t=5. 979, P<0. 01). The number of goblet cells on the 28th day after treatment was significantly higher than that before treatment(U=1806. 500,P<0. 01). On the 14th day after treatment,70％ of the patients indicated that the drug was non.irritating,and no patient had intolerable irritation affecting daily lives. All patients had good tolerance to this drug. Conclusions The use of 0. 3％ sodium hyaluronate eye drops can improve the symptoms and signs of mild to moderate dry eye,which can be widely used for mild.to.moderate dry eye patients in clinic.